Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Stem Cell Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for USP16 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | USP16 Recombinant Protein (Wild Type) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Active site intact for enzymatic assays. |
View USP16 Products |
| Catalytic Control | USP16 (C205S) Mutant Protein Catalytically inactive control for specificity validation and binding assays. Sequence Verified. |
View USP16 Products |
| Gene Delivery | USP16 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and overexpression validation. |
View USP16 Products |
| Validator | USP16 siRNA Set Target-specific knockdown verification in cell-based functional assays. |
View USP16 Products |
| Related Target A | USP1 Highly homologous DUB; essential counter-screening target to ensure small molecule selectivity. |
View USP1 Products |
| Related Target B | BMI1 Key Polycomb repressive complex 1 (PRC1) component; functionally opposes USP16 in stem cell regulation. |
View BMI1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| DUB Subfamily Off-target Screening | Highly purified USP homolog panels (USP1, USP2, USP7) strictly verified by mass spectrometry. |
| Assay False Positives (Covalent Inhibitors) | Catalytically inactive USP16 C205S mutant protein available for negative control binding assays. |
| Physiological Substrate Validation | Recombinant Histone H2A/H2B heterodimers available for nucleosome-level deubiquitination assays. |
| In Vitro Knockdown Verification | Sequence-validated siRNA pools included for target specificity and phenotype rescue checks. |
Live USP16 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for USP16 therapeutics is intensifying, with major players shifting focus from traditional broad-spectrum deubiquitinating enzyme (DUB) inhibitors to highly selective small molecule inhibitors. As first-generation DUB-targeted therapies reach clinical trials, the next wave of R&D is targeting USP16 due to its unique role in regulating histone H2A monoubiquitination (H2AK119ub) and its critical involvement in somatic stem cell self-renewal, Down syndrome-associated pathologies, and specific oncogenic pathways.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Academic Medical Centers, Biotech Startups | Solid Tumors, Down Syndrome Cognitive Deficits | Enzymatic Assay (Need High-Purity WT and C205S Mutant USP16) |
| PROTAC / Degrader | Targeted Protein Degradation (TPD) Specialists | Hematological Malignancies, Breast Cancer | Ubiquitination Kinetics (Need Sequence-Verified Lentivirus for Stable Reporter Lines) |
| Gene Therapy / RNAi | Preclinical Stage Consortia | Neurodegenerative Diseases, Stem Cell Aging | Target Knockdown Validation (Need High-Specificity siRNA Sets) |